Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Medera Completes Patient Dosing for Heart Failure Treatment
In This Article:
By Karen Roman
Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction.
Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had entered into a definitive merger agreement on September 2024.
“We are very excited and encouraged by these results, which indicate that our various new designs such as optimized dosages seem to be making differences,” said Ronald Li, Ph.D., Medera’s co-founder and CEO.
Contact:
Terms and Privacy Policy